Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Associated Therapies
-
Clinical Trials
Related News

Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention

First Posted Date
2012-11-30
Last Posted Date
2016-07-06
Lead Sponsor
Hyeon-Cheol Gwon
Target Recruit Count
100
Registration Number
NCT01738100
Locations
🇰🇷

Samsung Medical Center, Seoul, Gang nam-Gu, Ilwon-Dong, Korea, Republic of

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Phase 3
Completed
Conditions
Peripheral Artery Disease
Interventions
Drug: Ticagrelor
Drug: Clopidogrel
First Posted Date
2012-11-26
Last Posted Date
2017-10-30
Lead Sponsor
AstraZeneca
Target Recruit Count
13885
Registration Number
NCT01732822
Locations
🇻🇳

Research Site, Hochiminh, Vietnam

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
Drug: Ticagrelor
Drug: Clopidogrel
First Posted Date
2012-10-15
Last Posted Date
2015-05-05
Lead Sponsor
Rapid City Regional Hospital, Inc
Target Recruit Count
28
Registration Number
NCT01706510
Locations
🇺🇸

Regional Heart Doctors/Black Hills Cardiovascular Research, Rapid City, South Dakota, United States

Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study

First Posted Date
2012-10-04
Last Posted Date
2016-09-07
Lead Sponsor
Johannes Gutenberg University Mainz
Target Recruit Count
126
Registration Number
NCT01700322
Locations
🇩🇪

2 Medical Clinic, Mainz, Germany

VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel

First Posted Date
2012-09-13
Last Posted Date
2014-09-22
Lead Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Target Recruit Count
65
Registration Number
NCT01684813
Locations
🇪🇸

Hospital Universitario Virgen del Rocío, Seville, Spain

Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination

First Posted Date
2012-08-13
Last Posted Date
2012-08-13
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
60
Registration Number
NCT01663038
Locations
🇰🇷

Inje University Pusan Paik Hospital, Pusan, Korea, Republic of

PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants

Phase 3
Completed
Conditions
Acute Coronary Syndromes
Interventions
Drug: Clopidogrel
Drug: Prasugrel
First Posted Date
2012-07-16
Last Posted Date
2019-02-11
Lead Sponsor
Dong-A University
Target Recruit Count
70
Registration Number
NCT01641510
Locations
🇰🇷

DongA University Hospital, Busan, Korea, Republic of

Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.

Phase 4
Withdrawn
Conditions
Acute Myocardial Infarction
Interventions
Drug: Clopidogrel
First Posted Date
2012-07-10
Last Posted Date
2015-03-06
Lead Sponsor
Fundacja Ośrodek Badań Medycznych
Registration Number
NCT01636180
Locations
🇵🇱

Krakowskie Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii Carint Scanmed Sp. z o.o, Krakow, Poland

Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages

First Posted Date
2012-07-09
Last Posted Date
2017-03-10
Lead Sponsor
Ain Shams University
Target Recruit Count
32
Registration Number
NCT01635426
Locations
🇪🇬

Ain Shams University, Abbasiya, Cairo, Egypt

Residual Platelet Activity In Advanced Peripheral Artery Disease

First Posted Date
2012-06-25
Last Posted Date
2012-11-28
Lead Sponsor
University of Roma La Sapienza
Target Recruit Count
410
Registration Number
NCT01627431
Locations
🇮🇹

University of Florence - Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

🇮🇹

Sapienza- University of Rome -Azienda Policlinico Umberto I, Rome, Italy

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy